Zobrazeno 1 - 10
of 197
pro vyhledávání: ''
Publikováno v:
Tumori Journal. 107:424-431
Purpose: To explore the value of contrast-enhanced malignancy imaging features in secondary grade diagnosis of Breast Imaging Reporting and Data System for Ultrasonography (BI-RADS-US) type 4 breast lesions. Methods: After initial diagnosis by ultras
Autor:
Andrea Vingiani, Anna Borelli, Gianfranco Scaperrotta, Catherine Depretto, Francesco Cartia, Claudio Ferranti, Gabriele Presti, Alessandro Liguori
Publikováno v:
Tumori Journal. 106:491-496
Aim: To evaluate the presence of contrast enhancement at the site of calcifications on contrast-enhanced mammography (CEM) and histopathologic results at vacuum-assisted biopsy (VAB), and to examine the association with lesion size and immunohistoche
Autor:
Claudio Zamagni, A. Marino, Gianfranco Filippelli, Claudio Scavelli, Caterina Fontanella, Antonio Febbraro, Anna Maria Quaranta, Pasqualinda Ferrara, Paola Schiavone, Laura Orlando, Palma Fedele, Eufemia Stefania Lutrino, Guido Giordano, Gianluca Dima, Chiara Caliolo, Nicola Calvani, Saverio Cinieri, Mariangela Giampaglia, Daniela Rubino, Domenico Bilancia
Publikováno v:
Tumori
Background: Chemotherapy plus targeted therapy is the established treatment for human epidermal growth factor receptor 2 (HER2)–overexpressing breast cancer (BC). Limited data regarding the safety and activity of the combination of eribulin and tra
Autor:
Roberto Orecchia, Giulia Marvaso, Samantha Dicuonzo, Maria Cristina Leonardi, Barbara Alicja Jereczek-Fossa, E. Miglietta, Federica Cattani, Rosalinda Ricotti, Damaris Patricia Rojas
Publikováno v:
Tumori Journal. 106:518-523
Objective: To report treatment times (door to door) of adjuvant treatments of breast cancer (BC) with intensity-modulated radiotherapy (IMRT). Methods: Treatment times of 62 patients with BC on the TomoTherapy Hi-Art System were collected for the ana
Autor:
Dino Amadori, Silvia Mancini, Emanuele Crocetti, Alessandra Ravaioli, Fabio Falcini, Flavia Baldacchini, Rosa Vattiato, Orietta Giuliani
Publikováno v:
Tumori Journal. 105:483-487
Objectives: Prognostic definition and treatment of breast cancer are supported by multigene testing. A recent trial (TAILORx) provided evidence against the use of adjuvant chemotherapy in early breast cancer (HR+ HER2−) with an intermediate result
Autor:
Donato Casella, Vieri Scotti, Livia Marrazzo, Icro Meattini, Lorenzo Orzalesi, Carlotta Becherini, Pietro Garlatti, Simonetta Bianchi, Jacopo Nori, Luis Jose Sanchez, Marco Bernini, Stefania Pallotta, Silvia Nesi, Lorenzo Livi, Isacco Desideri
Publikováno v:
Tumori Journal. 105:205-209
Introduction: For a long time, accelerated partial breast irradiation (APBI) effectiveness for ductal carcinoma in situ (DCIS) has been debated, due to conflicting published results. Recent encouraging data from phase 3 trials reopened new perspectiv
Autor:
Viviana Sollazzo, Maria Cervotti, Gennaro Limite, Rosa Di Micco, Corrado Caiazzo, Emanuela Esposito, Pietro Forestieri, Carlo Varelli
Publikováno v:
Tumori Journal. 104:438-443
Purpose: In the last decade contrast-enhanced magnetic resonance imaging (MRI) has gained a growing role as a complementary tool for breast cancer diagnosis. Currently the relationship between the kinetic features of a breast lesion and pathologic pr
Publikováno v:
Tumori Journal. 104:116-120
Purpose: Breast is the leading site of cancer onset and death in Italy. Cases diagnosed in stage IV or that progress in metastatic phase represent a specific and challenging task for oncologists. Estimates on the burden of breast cancer (BC) in stage
Publikováno v:
Tumori Journal. 105:NP17-NP19
Purpose: The integration of expertise between oncologist and clinical biochemist for the monitoring and diagnosis of plasma cell dyscrasia is crucial. In some cases, medical laboratory scientists can provide an original contribution using the appropr
Autor:
Xiaopeng Hao, Yinglin Lu, Di Meng, Kun Chen, Xiqin Yang, Bingshui Xiu, Xiaojuan Lv, Yan Huang, Heqiu Zhang, Yan-Jun Zeng, Xiaoyan Feng
Publikováno v:
Tumori Journal. 102:264-269
Purpose Human mammaglobin (hMAM) is a breast tissue-specific marker that may have potency for the diagnosis of breast cancer. However, there is a lack of commercialization of anti-hMAM antibody made in China. Methods Immunoreactivities of 2 self-made